Nu Skin Enterprises (NUS)
NYSE:NUS
Top Page
Nu Skin
(NYSE:NUS)
Select Model
Select Model
Rating:55Neutral
Price Target:
$7.50
▼(-27.95% Downside)
Action:ReiteratedDate:03/21/26
The score reflects mixed fundamentals (profitability rebound and improved balance sheet offset by multi-year revenue decline and only moderate cash conversion) and notably weak technicals. Very low valuation and a solid dividend support the score, while cautious 2026 guidance and execution risk around Prism IO/India cap upside near-term.
Positive Factors
Improved balance sheet / net cash
Nu Skin entered 2026 with markedly improved leverage and a net cash posture (cash ≈ $240M vs debt $224M reported). This stronger capital structure provides durable financial flexibility to fund strategic initiatives, absorb top-line volatility, return capital, and invest in Prism IO or local manufacturing without immediate refinancing risk.
Negative Factors
Multi-year revenue decline and scale loss
A sustained fall in revenue erodes scale economics and dealer/distributor engagement in a direct-selling model. Continued top-line shrinkage pressures the company's ability to fund marketing, incentives, and new-market buildouts, making it harder to leverage its high gross margins into consistent operating earnings over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved balance sheet / net cash
Nu Skin entered 2026 with markedly improved leverage and a net cash posture (cash ≈ $240M vs debt $224M reported). This stronger capital structure provides durable financial flexibility to fund strategic initiatives, absorb top-line volatility, return capital, and invest in Prism IO or local manufacturing without immediate refinancing risk.
Read all positive factors
Nu Skin (NUS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$356.62M
Dividend Yield2.39%
Average Volume (3M)554.41K
Price to Earnings (P/E)3.0
Beta (1Y)1.18
Revenue Growth-12.10%
EPS GrowthN/A
CountryUS
Employees3,100
SectorConsumer Defensive
Sector Strength42
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)0.29
Shares Outstanding48,126,823
10 Day Avg. Volume573,976
30 Day Avg. Volume554,408
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)0.59
Price to Sales (P/S)0.32
P/FCF Ratio10.31
Enterprise Value/Market Cap1.35
Enterprise Value/Revenue0.32
Enterprise Value/Gross Profit0.47
Enterprise Value/Ebitda1.83
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.42
Revenue Forecast (FY)$1.53B
Nu Skin Business Overview & Revenue Model
Company Description
Nu Skin Enterprises, Inc. develops and distributes beauty and wellness products worldwide. It provides skin care systems, including ageLOC Spa systems, ageLOC Transformation anti-aging skin care systems, and ageLOC LumiSpa skin treatment and clean...
How the Company Makes Money
Nu Skin primarily makes money by selling its products through a direct-selling (multi-level) distribution model. Revenue is recognized from product sales to customers and to independent brand partners/distributors (often referred to as “sales lead...
Nu Skin Earnings Call Summary
Earnings Call Date:Feb 12, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 06, 2026
Earnings Call Sentiment Positive
The call highlights meaningful operational and financial improvements in 2025—notably strong adjusted EPS growth (~51%), gross margin expansion in the core business, improved operating margin, a healthier balance sheet, and sizeable strategic initiatives (Prism IO data assets and India entry). However, near-term headwinds include conservative 2026 revenue/EPS guidance, Q4 consolidated gross margin softness, FX impacts, a higher expected tax rate, and uncertainty around monetization timing for Prism IO and India ramp. Taken together, management demonstrated improved profitability and strategic positioning while acknowledging execution and timing risks that temper near-term top-line visibility.Positive Updates
Adjusted Earnings Per Share Growth
Adjusted EPS for full-year 2025 was $1.27 versus $0.84 in 2024, representing approximately 51% growth driven by gross margin expansion, selling expense optimization, and disciplined G&A management.
Negative Updates
Top-Line Pressure and Conservative 2026 Guidance
2026 revenue guidance is $1,350,000,000 to $1,500,000,000 (includes estimated FX headwind of ~$13–15M), with EPS projected at $0.80 to $1.20 versus $1.27 in 2025—reflecting conservative expectations and uneven near-term growth visibility.
Read all updates
Q4-2025 Updates
Positive
Negative
Adjusted Earnings Per Share Growth
Adjusted EPS for full-year 2025 was $1.27 versus $0.84 in 2024, representing approximately 51% growth driven by gross margin expansion, selling expense optimization, and disciplined G&A management.
Read all positive updates
Company Guidance
Nu Skin guided 2026 revenue of $1.35B–$1.50B (including an estimated $13M–$15M FX headwind, ~1%), with adjusted EPS of $0.80–$1.20 assuming a ~35% tax rate; they forecast Q1 revenue of $320M–$340M and Q1 EPS of $0.10–$0.20 (Q1 seasonally lowest), expect stronger back-half (Q3–Q4) contribution tied to the full consumer Prism IO launch, and target placing >100,000 Prism IO devices by year-end 2026 (management noted ~ $300/device ≈ $30M of device revenue potential) with subscription revenue driving >6x customer lifetime value and an aspiration to reach 10M households by 2030; 2025 anchors the outlook — revenue $1.49B, adjusted EPS $1.27 (≈51% YoY improvement), core gross margin 77.4% (up 80 bps), Q4 core gross margin 77.6% (up 100 bps), adjusted operating margin 6.7% (up 140 bps), Q4 revenue $370M and EPS $0.29, cash ≈ $240M, debt $224M (net cash position), operating cash flow $80.3M, $11M dividends, $20M buybacks (with $142.3M remaining authorization), and a 2025 R&D tax credit that lowered tax expense by ~$8.1M (2025 effective tax rate 18.8%).Nu Skin Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
63
Positive
Cash Flow
52
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.49B | 1.73B | 1.97B | 2.23B | 2.70B |
| Gross Profit | 1.03B | 1.18B | 1.36B | 1.59B | 2.02B |
| EBITDA | 143.14M | -78.83M | 202.98M | 174.97M | 368.48M |
| Net Income | 160.20M | -146.59M | 8.60M | 104.78M | 147.27M |
Balance Sheet | |||||
| Total Assets | 1.41B | 1.47B | 1.81B | 1.82B | 1.91B |
| Cash, Cash Equivalents and Short-Term Investments | 239.84M | 197.99M | 267.82M | 278.51M | 354.81M |
| Total Debt | 364.25M | 478.23M | 607.33M | 520.52M | 503.79M |
| Total Liabilities | 600.07M | 817.46M | 984.50M | 923.67M | 993.71M |
| Stockholders Equity | 805.24M | 651.46M | 821.97M | 897.30M | 912.77M |
Cash Flow | |||||
| Free Cash Flow | 46.01M | 70.16M | 60.15M | 49.01M | 72.97M |
| Operating Cash Flow | 80.29M | 111.74M | 118.64M | 108.06M | 141.58M |
| Investing Cash Flow | 170.66M | -37.96M | -134.50M | -67.08M | -88.73M |
| Financing Cash Flow | -202.40M | -133.18M | 10.73M | -99.50M | -104.70M |
Nu Skin Technical Analysis
Negative
10.41
Price Trends
8.56
Negative
9.29
Negative
9.75
Negative
Market Momentum
-0.31
Negative
41.85
Neutral
80.20
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NUS, the sentiment is Negative. The current price of 10.41 is above the 20-day moving average (MA) of 7.26, above the 50-day MA of 8.56, and above the 200-day MA of 9.75, indicating a neutral trend. The MACD of -0.31 indicates Negative momentum. The RSI at 41.85 is Neutral, neither overbought nor oversold. The STOCH value of 80.20 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NUS.
Nu Skin Risk Analysis
Nu Skin disclosed 12 risk factors in its most recent earnings report. Nu Skin reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Nu Skin Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $3.61B | 28.63 | 10.75% | ― | 13.80% | -25.02% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
55 Neutral | $356.62M | 2.96 | 20.36% | 2.39% | -12.10% | ― | |
52 Neutral | $980.11M | -3.02 | -2.50% | 3.51% | -1.34% | -73.59% | |
50 Neutral | $1.80B | -5.46 | -14.49% | ― | -5.68% | -358.36% | |
47 Neutral | $25.00B | 58.52 | -4.41% | 1.30% | -6.36% | -554.84% | |
45 Neutral | $115.66M | -5.47 | -15.42% | ― | -13.14% | 57.98% |
* Consumer Defensive Sector Average
NUS
Nu Skin
7.41
1.34
22.16%
EL
The Estée Lauder Companies
69.12
17.00
32.62%
COTY
Coty
2.05
-2.85
-58.16%
EPC
Edgewell Personal Care
20.98
-6.25
-22.94%
ELF
e.l.f. Beauty
61.16
7.28
13.51%
SKIN
Beauty Health
0.91
-0.14
-13.40%
Nu Skin Corporate Events
Business Operations and StrategyExecutive/Board Changes
Nu Skin Names Chelsea Lantz Interim Chief Financial Officer
Positive
Mar 20, 2026
On March 17, 2026, longtime Nu Skin Executive Vice President and CFO James D. Thomas resigned to pursue an external opportunity, and the board named Vice President and Corporate Controller Chelsea K. Lantz as interim CFO, effective March 18, 2026....
Business Operations and StrategyExecutive/Board Changes
Nu Skin Names Chayce Clark Chief Operating Officer
Positive
Mar 9, 2026
On March 5, 2026, Nu Skin’s board appointed longtime legal executive Chayce D. Clark as executive vice president, chief operating officer and chief legal officer, a move formalized in a March 9, 2026 announcement. Clark, who joined the compa...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.